+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07104565

Evaluation of Tafasitamab Safety and Tolerability in Adults With Primary Autoimmune Blood Cell Disorders Including ITP and wAIHA

Led by Incyte Corporation · Updated on 2026-10-30

56

Participants Needed

39

Research Sites

24 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of tafasitamab INCA000585 in adults who have primary autoimmune blood cell disorders, including primary immune thrombocytopenia ITP and primary warm autoimmune hemolytic anemia wAIHA. This is a Phase 2a, open-label, multicenter clinical trial focusing on treatment outcomes in these patients. Participants will receive intravenous infusions of tafasitamab at scheduled times as defined by the study protocol. The trial includes two experimental cohorts based on the specific autoimmune disorder one for primary ITP and another for primary wAIHA. The study will assess treatment effects up to 52 weeks, including response rates and duration of response. Throughout the study, participants will be monitored regularly for safety and treatment response. Assessments include tracking adverse events, platelet counts, hemoglobin levels, and serum concentrations of the study drug. Researchers will evaluate stable platelet and hemoglobin responses after Day 56 through Week 48, along with complete and partial remission rates at Weeks 24 and 48. The total participation may last up to approximately one year with ongoing evaluations to understand treatment impact and safety.

CONDITIONS

Brief Title

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Research Team

I

Incyte Corporation Call Center (US)

I

Incyte Corporation Call Center (ex-US)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here